Related Experiment Video
Updated: Jul 1, 2025
09:44
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
10.1K
Extravasation After [ 177 Lu]Lu-HA-DOTATATE Therapy
Daphne M V de Vries-Huizing1, Zing J Cheung1, Jeroen J M A Hendrikx
1From the Departments of Nuclear Medicine.
Clinical Nuclear Medicine
|March 11, 2024
Summary
Extravasation during peptide receptor radionuclide therapy (PRRT) is rare. This case report details a patient who experienced extravasation of [177Lu]Lu-HA-DOTATATE, with symptoms resolving without long-term complications.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmacology
Background:
- Peptide receptor radionuclide therapy (PRRT) is a targeted treatment for neuroendocrine tumors.
- Extravasation, the leakage of infused substances into surrounding tissues, is an infrequent complication of PRRT.
- Early identification and management are crucial for patient safety during PRRT.
Observation:
- A 74-year-old female patient with a neuroendocrine tumor undergoing PRRT experienced extravasation of 7.4 GBq [177Lu]Lu-HA-DOTATATE.
- The extravasation occurred due to a displaced intravenous catheter during infusion in the upper right arm.
- Planar scintigraphy confirmed radioactivity pooling in the affected arm.
Findings:
- Following extravasation, the patient presented with decreased swelling and increased erythema in the right upper arm within 24 hours.
- All symptoms resolved completely within one week.
- The patient experienced no complications during an 11-month follow-up period.
Implications:
- This case highlights that extravasation during PRRT, while concerning, can be managed effectively with conservative measures.
- Prompt recognition and monitoring can lead to favorable patient outcomes.
- Further research into preventative strategies and standardized management protocols for PRRT extravasation is warranted.
